Literature DB >> 11133854

Improvement of lacrimal function by topical application of CyA in murine models of Sjögren's syndrome.

K Tsubota1, H Fujita, K Tadano, T Takeuchi, T Murakami, I Saito, Y Hayashi.   

Abstract

PURPOSE: The object of this study was to evaluate improvement of lacrimal gland (LG) function after topical cyclosporin A (CyA).
METHODS: Topical CyA (0.01% and 0.1%) was applied to two mouse models of Sjögren's syndrome, the NFS/sld after thymectomy and the nonobese diabetic (NOD) mouse, and the functional integrity of the lacrimal gland was evaluated by measuring basal and stimulated tear secretion and its histologic integrity by examining it for apoptosis and lymphocyte invasion.
RESULTS: After treatment with CyA at 0.1% in the NFS/sld mice, tear function increased, and there was a decrease in lymphocyte infiltration of the LG and a decrease in apoptotic figures among the acinar cells. In the NOD mice, tear function also improved, but there was no associated decrease in lymphocyte infiltration. However, the expression of Fas ligand (FasL) in NOD mice by infiltrating lymphocytes was suppressed with 0. 1% CyA eye drops.
CONCLUSIONS: CyA appears to improve tear secretion in mouse models of Sjögren's syndrome by preventing lymphocyte-induced apoptosis of acinar cells. In one model this was achieved by preventing lymphocyte infiltration and in the other by reducing expression of FasL expression on infiltrating lymphocytes.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11133854

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  13 in total

Review 1.  Experience with experimental biological treatment and local gene therapy in Sjogren's syndrome: implications for exocrine pathogenesis and treatment.

Authors:  B M Lodde; B J Baum; P P Tak; G Illei
Journal:  Ann Rheum Dis       Date:  2006-07-31       Impact factor: 19.103

2.  Neurologic evaluation of acute lacrimomimetic effect of cyclosporine in an experimental rabbit dry eye model.

Authors:  Hiroshi Toshida; Doan H Nguyen; Roger W Beuerman; Akira Murakami
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-02-14       Impact factor: 4.799

Review 3.  Autoimmunity in the pathogenesis and treatment of keratoconjunctivitis sicca.

Authors:  Katy C Liu; Kyle Huynh; Joseph Grubbs; Richard M Davis
Journal:  Curr Allergy Asthma Rep       Date:  2014-01       Impact factor: 4.806

4.  The efficacy of topical 0.05 % cyclosporine A in patients with dry eye disease associated with Sjögren's syndrome.

Authors:  Hülya Devecı; Senol Kobak
Journal:  Int Ophthalmol       Date:  2014-01-19       Impact factor: 2.031

Review 5.  Mouse Models of Primary Sjogren's Syndrome.

Authors:  Young-Seok Park; Adrienne E Gauna; Seunghee Cha
Journal:  Curr Pharm Des       Date:  2015       Impact factor: 3.116

Review 6.  Sjögren syndrome: what and where are we looking for?

Authors:  Cintia S de Paiva; Eduardo Melani Rocha
Journal:  Curr Opin Ophthalmol       Date:  2015-11       Impact factor: 3.761

7.  Amelioration of lacrimal gland inflammation by oral administration of K-13182 in Sjögren's syndrome model mice.

Authors:  T Nishiyama; K Mishima; K Obara; H Inoue; T Doi; S Kondo; M Saka; Y Tabunoki; Y Hattori; T Kodama; K Tsubota; I Saito
Journal:  Clin Exp Immunol       Date:  2007-07-05       Impact factor: 4.330

8.  Anti-inflammatory effects of rebamipide eyedrop administration on ocular lesions in a murine model of primary Sjögren's syndrome.

Authors:  Rieko Arakaki; Hiroshi Eguchi; Akiko Yamada; Yasusei Kudo; Akihiko Iwasa; Tserennadmid Enkhmaa; Fumika Hotta; Sayaka Mitamura-Aizawa; Yoshinori Mitamura; Yoshio Hayashi; Naozumi Ishimaru
Journal:  PLoS One       Date:  2014-05-27       Impact factor: 3.240

9.  Rapamycin Eye Drops Suppress Lacrimal Gland Inflammation In a Murine Model of Sjögren's Syndrome.

Authors:  Mihir Shah; Maria C Edman; Srikanth Reddy Janga; Frances Yarber; Zhen Meng; Wannita Klinngam; Jonathan Bushman; Tao Ma; Siyu Liu; Stan Louie; Arjun Mehta; Chuanqing Ding; J Andrew MacKay; Sarah F Hamm-Alvarez
Journal:  Invest Ophthalmol Vis Sci       Date:  2017-01-01       Impact factor: 4.799

Review 10.  Recent Advances in Mouse Models of Sjögren's Syndrome.

Authors:  Yunzhen Gao; Yan Chen; Zhongjian Zhang; Xinhua Yu; Junfeng Zheng
Journal:  Front Immunol       Date:  2020-06-30       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.